Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Get Paid 16.4% Yield To Wait For Big Upside To Play Out

2018-07-17 seekingalpha
This is a situation where "Heads I win (if the merger goes through), tail I win too (if the merger does not go through)".
AMID PVAC PVAYQ PVA

1
Strategies For The Bursting Bond Bubble

2018-07-11 seekingalpha
This year’s increased stock market volatility and sharp declines in the emerging markets are the result of rising interest rates. If interest rates revert to the normal 2007 pre-financial crisis levels, a process not even halfway complete, the potential for significant declines in equity, bond and real estate markets becomes a serious and present risk. This letter will address ways to help preserve your wealth if rising interest rates trigger significant market declines.
AMID CLMT SXE

4
AMID / American Midstream Partners LP 8-K (Current Report)

2018-07-07 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
AMID

5
American Midstream: Shale Growth To Be Beneficial

2018-07-06 seekingalpha
American Midstream is currently in the end stages of an ambitious $1.8 billion growth program but still has some opportunities for further growth elsewhere.
ETP.PRC ETP AMID PVAC PVAYQ PVA

5
American Midstream And Southcross Energy Merger: Why The Wait?

2018-06-26 seekingalpha
AMID is acquiring SXE in a 1-for-0.16 all-stock deal (SXE investors get 0.16 shares of AMID for each share of SXE).
AMID SXE

9
A Discounted Backdoor Into An 18% Yield - Buyout Should Close Very Soon

2018-06-23 seekingalpha
The deal is supposed to close by the end of June - all board, unitholder and state approvals have been met.
AMID DKL GPP SXE

6
AMID / American Midstream Partners LP 8-K (Current Report)

2018-06-21 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
AMID

7
TransCanada: Strong Prospects For 10% Dividend Growth

2018-06-21 seekingalpha
TransCanada is one of the largest pipeline operators in North America and is far more than just the Keystone Pipeline.
TRP CPGX AMID TRP CGGXP

7
AMID / American Midstream Partners LP 8-K (Current Report)

2018-06-01 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
AMID

105
Top MLP Losses in the Week Ending May 25

2018-05-29 marketrealist
Legacy Reserves (LGCY), the upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP loss last week. Legacy Reserves fell 36.2% mainly due to the weakness in crude oil prices. Although Legacy Reserves has fallen significantly from its YTD highs, it’s still up 217.4% in 2018. The stock might continue to see high volatility in the near term due to strong movements in crude oil prices.
CCLP LGCYP SDLP LGCYO AMID LGCY SDRL SXE PAA BPL HCLP SNMP

5
These 7 MLPs Offer Yields above 12%

2018-05-18 marketrealist
Currently, the Alerian MLP Index (^AMZ) has a yield higher than 8%. Even with the ten-year Treasury yield’s rise above 3%, AMZ offers an attractive spread of 5% over the Treasury yield. However, there are some MLPs that are trading at yields above 12%. In this series, we’ll take a look at seven MLPs. We’ll see whether or not Wall Street analysts recommend these MLPs.
AMID EEP

4
AMID / American Midstream Partners LP 10-Q (Quarterly Report)

2018-05-15 sec.gov
Document UNITED STATES
AMID

4
AMID / American Midstream Partners LP FORM 8-K (Current Report)

2018-05-15 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AMID

5
Opportunity To Invest In This 16% Yielder Along With An Experienced Manager That Owns 26% Of The Float

2018-05-13 seekingalpha
There's plenty of reasons to be positive on the stock, including growth projects and the synergies that will be created with the Southcross Merger.
JPEP AMID SXE

6
AMID / American Midstream Partners LP NT 10-Q

2018-05-11 sec.gov
NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AMID

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to AMID / American Midstream Partners LP on message board site Silicon Investor.

Laramide Resources Ltd (LAM.V) Pyramid That IPO
Laramide Resources, Great New Property www.stockgeneration.com -- Pyramid Scam
PYRAMID ENERGY INC (PYI.A) Laramide Resources (T.LAM)
CUSIP: 02752P100